Second-Line Treatment Options for Hepatocellular Carcinoma: Current Landscape and Future Direction

Area of Science:

• Hepatology
• Medical Oncology
• Cancer Research

Background:

• Hepatocellular carcinoma (HCC) is a major global health concern with increasing incidence.
• Recent years have seen significant advancements in systemic therapies for HCC.
• New agents include immune checkpoint inhibitors and vascular endothelial growth factor (VEGF) inhibitors.

Purpose of the Study:

• To review current second-line systemic treatment options for HCC.
• To discuss future perspectives in HCC treatment strategies.

Main Methods:

• Review of clinical data on systemic therapies for HCC.
• Analysis of recent treatment approvals and survival outcomes.

Main Results:

• Multiple systemic agents are now available, including cabozantinib, regorafenib, and ramucirumab.
• The combination of atezolizumab plus bevacizumab has demonstrated superior overall survival in HCC.
• This combination has become the preferred first-line treatment, surpassing sorafenib and lenvatinib.

Conclusions:

• The treatment landscape for HCC is rapidly evolving with novel systemic options.
• Atezolizumab plus bevacizumab represents a significant breakthrough in first-line HCC therapy.
• Further research into second-line treatments and future therapeutic directions is warranted.